A regenerative medicine company anchored in research conducted at Carnegie Mellon University, FluidForm Inc, develops solutions for issues in the space of functional human tissue research, repair, and replacement. The firm's primary technology, FRESH 3D, is a printing technology used for the biofabrication of tissues and organs. Effectively the firm offers the ability to build human tissues for drug discovery, surgical repair, and organ transplant - accomplished through AI and machine learning, advanced materials science, 3D printing, and synthetic biology. The technology produces real functional beating human ventricles and heart valves, recreates complex branding vasculature, promotes tissue regeneration, and can be scaled up to full-size organs. The two initial programs for this technology are an in-vitro human model that detects complex arrhythmias early in the pre-clinical discovery process and a valve that reduces the risk of calcification for heart valve diseases.
